Effect of ipsilateral subthalamic nucleus lesioning in a rat parkinsonian model: study of behavior correlated with neuronal activity in the pedunculopontine nucleus.
OBJECTIVE
The purpose of this study was to investigate the spontaneous behavioral changes and the alteration of neuronal activities in the pedunculopontine nucleus (PPN) after ipsilateral subthalamic nucleus (STN) lesioning by kainic acid in a rat parkinsonian model created by lesioning with 6-hydroxydopamine (6-OHDA).


METHODS
Assumptions about the mechanisms mediating the effects of lesioning of the nigrostriatal dopaminergic pathway by 6-OHDA and the effects of STN lesioning were examined behaviorally by means of apomorphine-induced rotational behavior and forepaw-adjusting steps. The authors subsequently investigated the alteration of neuronal activities in the PPN to compare them with the behavioral changes in rat parkinsonian models.


CONCLUSIONS
The results demonstrated that STN lesioning induced behavioral improvement in rat parkinsonian models. This result, which confirms previously held assumptions, may account for the therapeutic effect of STN stimulation in Parkinson disease. The alteration of the neuronal activities in the PPN units also indicates that the PPN units are responsible for the improvement in motor symptoms observed after STN lesioning in rat parkinsonian models.
Department of Neurosurgery, Medical Research Center, Brain Korea 21 Project for Medical Science and Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Mi Fa
MF
Jeon
Yoon
Y
Ha
Yoon Hee
YH
Cho
Bae Hwan
BH
Lee
Yong Gou
YG
Park
Jin Woo
JW
Chang
D018663:Adrenergic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000503:physiopathology; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000009:adverse effects; D007839:Functional Laterality / Q000502:physiology; D007608:Kainic Acid / Q000008:administration & dosage / Q000009:adverse effects; D008124:Locomotion / Q000187:drug effects; D008636:Mesencephalon / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects*; D016627:Oxidopamine / Q000008:administration & dosage / Q000009:adverse effects; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000503:physiopathology*; D011149:Pons / Q000187:drug effects* / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012399:Rotation; D013378:Substantia Nigra / Q000503:physiopathology; D020531:Subthalamic Nucleus / Q000503:physiopathology*
D018663:Adrenergic Agents; D018690:Excitatory Amino Acid Agonists; D016627:Oxidopamine; D007608:Kainic Acid